

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) An isolated polynucleotide comprising a sequence selected from the group consisting of:
  - (a) the sequence provided in SEQ ID NO:343;
  - (b) the complement of the sequence provided in SEQ ID NO:343;
  - ~~(c) sequences consisting of at least 20 contiguous residues of the sequence provided in SEQ ID NO:343;~~
  - ~~(d) sequences that hybridize to the sequence provided in SEQ ID NO:343, under highly stringent conditions;~~
  - ~~(e) sequences having at least 75% identity to the sequence of SEQ ID NO:343;~~
  - ~~(f) sequences having at least 90% identity to the sequence of SEQ ID NO:343; and~~
  - ~~(g)~~(c) degenerate variants of the sequence provided in SEQ ID NO:343, wherein said variants encode the polypeptide encoded by SEQ ID NO:343.
2. (Canceled)
3. (Currently Amended) An expression vector comprising a polynucleotide of claim 1 or claim 18 operably linked to an expression control sequence.
4. (Original) A host cell transformed or transfected with an expression vector according to claim 3.

5.-10. (Canceled)

11. (Currently Amended) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising the polynucleotide according to claim 1 or claim 18.

12.-17. (Canceled)

18. (New) An isolated polynucleotide for use in the detection of breast cancer, comprising a sequence selected from the group consisting of sequences having at least 90% identity to the polynucleotide of SEQ ID NO:343, wherein said sequences hybridize to the polynucleotide of SEQ ID NO:343 under highly stringent conditions.